“ EGCG enhanced the antiproliferation and VEGF secretion-reducing effects of sunitinib in the three tested cell lines.”
“ EGCG potentially synergizes with sunitinib due to its ability to suppress the IRS/MAPK signaling induced by sunitinib.”
“In vivo, immunohistochemical analyses demonstrated marked suppression of the IRS/MAPK/p-S6K1 signaling cascade by EGCG , especially after sunitinib treatment.”
“In vivo, EGCG administration at 4 h after sunitinib treatment resulted in greater tumor shrinkage and antiangiogenesis than with sunitinib alone.”